Loading...
XCNQENBI
Market cap986kUSD
Dec 23, Last price  
0.16CAD
1D
-5.88%
1Q
52.38%
IPO
-74.60%
Name

Entheon Biomedical Corp

Chart & Performance

D1W1MN
XCNQ:ENBI chart
P/E
P/S
5.66
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.15%
Rev. gr., 5y
%
Revenues
250k
+31.97%
00000021,670189,677250,323
Net income
-300k
L-95.73%
-8,862-1,859-144,981-157,534-667,267-4,378,032-8,669,912-7,031,923-300,001
CFO
-360k
L-81.59%
-8,784-2,033-67,492-221,312-102,317-2,837,522-5,615,218-1,954,608-359,929
Earnings
Dec 27, 2024

Profile

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
IPO date
May 03, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑112022‑112021‑112020‑112020‑032019‑112019‑032018‑032017‑032016‑03
Income
Revenues
250
31.97%
190
775.30%
Cost of revenue
564
3,790
Unusual Expense (Income)
NOPBT
(314)
(3,600)
NOPBT Margin
Operating Taxes
4,970
Tax Rate
NOPAT
(314)
(8,571)
Net income
(300)
-95.73%
(7,032)
-18.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
155
Net debt
(350)
(705)
Cash flow
Cash from operating activities
(360)
(1,955)
CAPEX
Cash from investing activities
24
586
Cash from financing activities
FCF
(314)
(8,175)
Balance
Cash
345
680
Long term investments
5
25
Excess cash
337
696
Stockholders' equity
316
615
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
5,909
5,909
Price
0.01
-66.67%
0.03
-94.44%
Market cap
59
-66.67%
177
-93.95%
EV
(291)
(528)
EBITDA
(314)
(3,598)
EV/EBITDA
0.93
0.15
Interest
1,489
Interest/NOPBT